Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics. That flywheel is the moat. The three companies owning the installed bases to build it are Intuitive Surgical (NASDAQ: ISRG | ISRG Price Prediction), Medtronic (NYSE: MDT), and Stryker (NYSE: SYK). With all three trading well off their 2026 highs, the AI sleeper thesis looks more compelling.
3. Stryker (Mako and the New Ortho Tech Stack)
Stryker is the diversified medtech giant with the Mako robotic orthopedic franchise. Q1 FY26 showed adjusted EPS of $2.60, which missed the $2.98 estimate, as well as revenue of $6.02 billion, which came in short of the $6.33 billion consensus. CEO Kevin Lobo cited a March 11, 2026, cybersecurity incident and $118 million in structural optimization charges that compressed adjusted operating margin to 21.1% from 22.9%.
The AI angle lives in the newly carved-out Ortho Tech business, which combines Mako robotic-assisted surgery with power tools, cutting accessories, and enabling technologies. Knees grew 4.7% and hips 3.7%, both Mako-tethered categories. Lobo said, “I am pleased with our team’s ability to recover quickly from the cyber incident…. We remain committed to meeting our full year guidance.” Guidance was maintained at 8.0% to 9.5% organic sales growth and adjusted EPS of $14.90 to $15.10. The risk is that Mako revenue is bundled, so investors cannot isolate the AI orthopedics flywheel. Shares are down 21.3% over the past year.
2. Medtronic (Hugo Goes Live)
Medtronic took its biggest step into the robotics race when the Hugo robotic-assisted surgery system received U.S. FDA clearance, with first cases completed in February 2026. Q3 FY26 revenue of $9.017 billion beat the $8.892 billion estimate, and non-GAAP EPS of $1.36 topped the $1.3351 consensus. Cardiac Ablation Solutions stood out, with pulsed field ablation driving revenue up 80% overall and 137% in the United States.
Beyond Hugo, Medtronic cleared the Stealth AXiS Surgical System for spinal procedures and secured a CE Mark for the Sphere-360 mapping catheter, with AI-adjacent mapping and navigation embedded in both. CEO Geoff Martha said, “Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance…. It’s an exciting time for Medtronic.” Non-GAAP gross margin slipped to 64.9% from 66.6%, and a $185 million tariff headwind is baked into FY26 guidance of about 5.5% organic growth and $5.62 to $5.66 EPS. At a forward P/E of 14x and analyst target of $108, the diversified med-device exposure looks attractively priced after a 20.2% year-to-date drawdown.
1. Intuitive Surgical (the Data Flywheel Leader)
Intuitive Surgical is the cleanest expression of the thesis. Q1 FY26 non-GAAP EPS of $2.50 beat the $2.11 estimate by 18.66%, the fourth consecutive EPS beat. Revenue of $2.77 billion grew 22.96% year over year, anchored by $1.69 billion in Instruments & Accessories, the high-margin razor-blade line that scales with procedure volume.
The installed base is the moat. Some 11,395 da Vinci systems (up 12%) and 1,041 Ion systems (up 22%) feed procedural data back to Intuitive’s digital platforms for surgeon analytics and training. Of the 431 da Vinci placements in the quarter, 232 were da Vinci 5 units, the AI-ready next-generation platform. Procedures grew 16% for da Vinci and 39% for Ion. Operating income jumped 47.95%, and the company holds $7.98 billion in cash after repurchasing 2.3 million shares for $1.1 billion. CEO Dave Rosa said the quarter “was marked by expanded adoption of our da Vinci, Ion, and digital platforms.” FY26 guidance calls for 13.5% to 15.5% da Vinci procedure growth. However, tariff exposure across Mexico, Germany, and China is embedded as a 1.0% margin headwind. With shares down 24.3% year to date, institutional patience is being tested while insiders accumulate equity grants.
The Verdict
Surgical robotics platforms are becoming AI-enabled systems whose data flywheels create durable moats, yet the market treats this thesis as immaterial. Intuitive Surgical is the purest expression, with the largest robotic installed base in healthcare and a digital platform that scales with every procedure. Medtronic is the diversified med-device hedge, now with the Hugo system cleared and the fastest-growing PFA franchise in cardiac care. Stryker is the orthopedic specialist whose Mako story is intact but temporarily clouded by a cyber incident and one-time charges. Together, they offer exposure to AI in operating rooms without software-stock multiples.
Top Gaining Stocks
Top Losing Stocks